Drug Trial Radar · NCT04847440
A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection
Last checked: Nov 19, 2026Latest source record: Nov 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
40
Actual
Start
Mar 30, 2021
Primary completion
Sep 1, 2022
Study completion Sep 1, 2022
Sponsor
- Lead sponsor
- Antios Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blinded, placebo-controlled, multi center, dose ranging study of safety and efficacy in both volunteers with chronic hepatitis B virus infection and in volunteers with hepatitis D virus coinfection. Volunteers will be administered multiple oral doses of ATI-2173 and assessed for safety and efficacy including blood tests to show how the body metabolizes and eliminates the investigational drug as well as how the drug effects the virus infection.
Conditions
- Hepatitis B, Chronic
- Hepatitis D
Interventions
ATI-2173Drug
ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth. Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
VireadDrug
Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
AB-729Drug
AB-729 is a potent, selective, subcutaneously administered, N-acetylgalactosamine (Ga1NAc)-conjugated small interfering ribonucleic acid (siRNA) inhibitor of HBV
Primary outcomes
What the sponsor says the trial is designed to measure.
- The percentage of subjects who experienced at least 1 treatment-emergent adverse event (TEAE)Time frame: Through study completion, an average of 1 year
- The percentage of subjects who experienced at least one treatment emergent serious AE (SAE).Time frame: Through study completion, an average of 1 year
- Percentage of subjects who experienced a treatment-emergent dose limiting toxicity (DLT)Time frame: Through study completion, an average of 1 year
- Percentage of subjects who experienced at least one treatment emergent Grade 1, 2, 3, 4 or 5 laboratory abnormalityTime frame: Through study completion, an average of 1 year
- Percentage of subjects who discontinued study drug due to a TEAETime frame: Through study completion, an average of 1 year
- Alanine aminotransferase and aspartate aminotransferase levels versus timeTime frame: Through study completion, an average of 1 year
- Time to HBV viral load relapse in HBV-infected subjectsTime frame: Through study completion, an average of 1 year
- The reduction of HDV RNA on-treatment for HBV/HDV coinfected subjectsTime frame: Through study completion, an average of 1 year
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Republican Clinical Hospital "Timofei Mosneaga" Arensia EM Unit
Chisinau, Republic of Moldova, Moldova
Medical Center of Limited Liability Company "Harmoniya krasy"
Kyiv, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.